An 8-Month Phase 3, Open-Label Study With a Blinded Reversal Phase to Evaluate the Safety and Tolerability of TAK-491 in Subjects With Essential Hypertension.
Phase of Trial: Phase III
Latest Information Update: 24 Jan 2015
At a glance
- Drugs Azilsartan medoxomil (Primary)
- Indications Essential hypertension
- Focus Registrational; Therapeutic Use
- Sponsors Takeda Global Research and Development Center
- 21 Jul 2010 Additional trial identifier U1111-1113-9088 identified as reported by ClinicalTrials.gov.
- 26 Jun 2009 Actual patient number (418) added as reported by ClinicalTrials.gov.
- 26 Jun 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.